Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
McKinsey
Harvard Business School
Deloitte
Moodys
Mallinckrodt
Julphar
Healthtrust
AstraZeneca

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,784,197

« Back to Dashboard

Summary for Patent: 6,784,197
Title: 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract:The invention concerns 2-oxo-1-pyrrolidine derivatives of formula (I) wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy. ##STR1##
Inventor(s): Differding; Edmond (Louvain-la-Neuve, BE), Kenda; Benoit (Emines, BE), Lallemand; Benedicte (Waimes, BE), Matagne; Alain (Gerpinnes, BE), Michel; Philippe (Beersel, BE), Pasau; Patrick (Chastre, BE), Talaga; Patrice (Watermael-Boitsfort, BE)
Assignee: UCB S.A. (Brussels, BE)
Application Number:10/204,266
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,784,197

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Try a Free Trial
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Try a Free Trial
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Try a Free Trial
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,784,197

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004297Feb 23, 2000
PCT Information
PCT FiledFebruary 21, 2002PCT Application Number:PCT/EP01/01992
PCT Publication Date:August 30, 2001PCT Publication Number: WO01/62726

Non-Orange Book US Patents Family Members for Patent 6,784,197

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,034,958 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Try a Free Trial
7,358,276 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Try a Free Trial
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Try a Free Trial
6,911,461 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,784,197

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 282592 ➤ Try a Free Trial
Austria 304999 ➤ Try a Free Trial
Austria 325093 ➤ Try a Free Trial
Austria 445597 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Cerilliant
Teva
Medtronic
US Department of Justice
Citi
AstraZeneca
Deloitte
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.